When should we start treatment for relapsed multiple myeloma patients?
Immune checkpoint inhibitors for cutaneous T-cell lymphoma
Novel ALL treatment strategies: inotuzumab ozogamicin
Germline predispositions in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML)
Jane E. Churpek
Indications for the use of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma